Vanguard Group
ETON icon

Vanguard Group’s Eton Pharmaceutcials ETON Stock Holding History

Vanguard Group’s Portfolio ETON Stock Details ETON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$22.8M Buy
1,348,668
+4,553
+0.3% +$80.1K ﹤0.01% 2557
2025
Q3 		$29.2M Buy
1,344,115
+31,942
+2% +$530K ﹤0.01% 2441
2025
Q2 		$18.7M Buy
1,312,173
+211,210
+19% +$3.34M ﹤0.01% 2588
2025
Q1 		$14.3M Buy
1,100,963
+37,256
+4% +$563K ﹤0.01% 2656
2024
Q4 		$14.2M Buy
1,063,707
+36,019
+4% +$365K ﹤0.01% 2767
2024
Q3 		$6.17M Hold
1,027,688
– – ﹤0.01% 3180
2024
Q2 		$3.38M Hold
1,027,688
– – ﹤0.01% 3400
2024
Q1 		$3.85M Hold
1,027,688
– – ﹤0.01% 3395
2023
Q4 		$4.5M Buy
1,027,688
+51,252
+5% +$205K ﹤0.01% 3330
2023
Q3 		$4.07M Hold
976,436
– – ﹤0.01% 3333
2023
Q2 		$3.41M Sell
976,436
-3,847
-0.4% -$14.1K ﹤0.01% 3469
2023
Q1 		$3.77M Buy
980,283
+55,180
+6% +$201K ﹤0.01% 3433
2022
Q4 		$2.61M Buy
925,103
+389
+0% +$1.05K ﹤0.01% 3568
2022
Q3 		$1.94M Buy
924,714
+51,843
+6% +$129K ﹤0.01% 3755
2022
Q2 		$2.29M Hold
872,871
– – ﹤0.01% 3751
2022
Q1 		$3.81M Sell
872,871
-5,531
-0.6% -$21.8K ﹤0.01% 3657
2021
Q4 		$3.77M Buy
878,402
+11,937
+1% +$57.1K ﹤0.01% 3770
2021
Q3 		$4.37M Buy
866,465
+4,925
+0.6% +$25.6K ﹤0.01% 3748
2021
Q2 		$5.31M Buy
861,540
+150,681
+21% +$1.12M ﹤0.01% 3567
2021
Q1 		$5.2M Sell
710,859
-156,388
-18% -$1.33M ﹤0.01% 3512
2020
Q4 		$7.05M Buy
867,247
+304,215
+54% +$2.35M ﹤0.01% 3172
2020
Q3 		$4.45M Buy
563,032
+204,872
+57% +$1.4M ﹤0.01% 3206
2020
Q2 		$1.95M Buy
358,160
+75,314
+27% +$374K ﹤0.01% 3439
2020
Q1 		$1.16M Buy
282,846
+1,200
+0.4% +$7K ﹤0.01% 3453
2019
Q4 		$2.03M Buy
281,646
+24,096
+9% +$149K ﹤0.01% 3445
2019
Q3 		$1.63M Buy
257,550
+228,788
+795% +$1.46M ﹤0.01% 3514
2019
Q2 		$227K Buy
28,762
+1,800
+7% +$14K ﹤0.01% 3958
2019
Q1 		$216K Buy
+26,962
New +$187K ﹤0.01% 3909

Other funds holding ETON

OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
NPT
National Philanthropic Trust Jenkintown, Pennsylvania $9.38B AUM 33.37% 1-Year Est. Return
WIM
Westside Investment Management Santa Monica, California $761M AUM 39.85% 1-Year Est. Return
OAM
Oberweis Asset Management Lisle, Illinois $3.39B AUM 105.5% 1-Year Est. Return

Vanguard Group's ETON Position: Q4 2025 in Review

Vanguard Group increased its Eton Pharmaceutcials (ETON) stake by 0.34% in Q4 2025, buying an estimated $80.1K and bringing the position to 1,348,668 shares worth $22.8M. The position accounts for ﹤0.01% of the portfolio, ranked #2557.

Vanguard Group first reported a position in ETON in Q1 2019 and has held it in 28 quarters since. The position peaked at $29.2M in Q3 2025. 104 funds tracked by Wall St. Rank hold ETON as of Q4 2025.

  • Vanguard Group held 1,348,668 shares of Eton Pharmaceutcials worth $22.8M as of Q4 2025.
  • Vanguard Group bought 4,553 Eton Pharmaceutcials shares in Q4 2025, an estimated $80.1K.
  • Eton Pharmaceutcials made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #2557 holding.
  • Vanguard Group first reported a position in Eton Pharmaceutcials in Q1 2019 and has held it in 28 quarters since.
  • Vanguard Group's Eton Pharmaceutcials position peaked at $29.2M in Q3 2025.
  • 104 funds tracked by Wall St. Rank held Eton Pharmaceutcials as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.